Solvonis Therapeutics (LSE:SVNS) announced a corporate restructuring aimed at optimizing its operations and sharpening its focus on research and development. The reorganization includes restructuring its subsidiaries in Ireland, the UK, and the US, alongside the divestment of its non-core unit, Graft Polymer IP Limited. This move is designed to consolidate intellectual property assets and reinforce the company’s R&D capabilities. Additionally, Solvonis issued new shares to settle historical liabilities and granted share options to its CEO and non-executive directors, underlining its commitment to strategic transformation and stakeholder alignment.
More about Solvonis Therapeutics plc
Solvonis Therapeutics plc is a London-based biopharmaceutical company listed on the London Stock Exchange. The company develops innovative small-molecule therapies targeting central nervous system (CNS) disorders, including addiction, psychiatric, and neurological conditions. Its leading programs focus on treatments for Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), advancing both repurposed and novel compounds to address unmet medical needs.
Leave a Reply